Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder | Zendy

ChiUn Pae | Zendy; ShengMin Wang | Zendy; HansJürgen Möller | Zendy; Soo-Jung Lee | Zendy; Ashwin A. Patkar | Zendy; Praksh S. Masand | Zendy; Alessandro Serretti | Zendy

Open Access

Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder

Author(s) -

ChiUn Pae,

ShengMin Wang,

HansJürgen Möller,

Soo-Jung Lee,

Ashwin A. Patkar,

Praksh S. Masand,

Alessandro Serretti

Publication year - 2015

Publication title -

journal of psychiatry and neuroscience

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.767

H-Index - 99

eISSN - 1488-2434

pISSN - 1180-4882

DOI - 10.1503/jpn.140120

Subject(s) - vortioxetine , major depressive disorder , placebo , randomized controlled trial , hamilton rating scale for depression , antidepressant , medicine , odds ratio , confidence interval , depression (economics) , rating scale , clinical trial , adverse effect , psychiatry , psychology , mood , developmental psychology , alternative medicine , pathology , economics , macroeconomics , hippocampus

Vortioxetine was approved by the U.S. Food and Drug Administration (FDA) in September 2013 for treating major depressive disorder (MDD). Thus far, a number of randomized, double-blind, placebo-controlled clinical trials (RCTs) of vortioxetine have been conducted in patients with MDD. We performed a meta-analysis to increase the statistical power of these studies and enhance our current understanding of the role of vortioxetine in the treatment of MDD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research